Sage Journals: Discover world-class research

Abstract

Keywords

immunotherapy passive active Fab fragments poisoning acute Antivenin

Get full access to this article

View all access options for this article.

References

Pichot A. Louis Pasteur: Écrits Scientifiques et Médicaux. Paris : GF-Flammarion, 1994.

Sewall H. Experiments on the preventive inoculation of rattlesnake venom. Journal of Physiology (London) 1887 ; 8: 203-210.

Calmette A. Venoms, venomous animals, and serotherapy. Paris : Masson, 1908.

Brazil V. Contribucao ao estudo de venemo phidico: III. Tratamentos das mordeduras das cobras. Revista Medical de Sao Paolo ( Brazil) 1901; 4: 375-380.

Erlich P. On immunity with special reference to cell life. Proceedings of the Royal Society of London. Series B: Biological Sciences (London) 1900; 66: 424-448.

Butler VP Jr, Chen JP Digoxin specific antibodies. Proceedings of the National Academy of Sciences of the United States of America ( Washington ) 1967; 57: 71-78.

Smith TW , Butler VP Jr , Haber E. Determination of therapeutic and toxic digoxin concentrations by radioimmunoassay . New England Journal of Medicine (Boston ) 1969; 294: 797-800.

Smith TW Radioimmunoassay for serum digitoxin concentrations. Methodology and clinical experience. Journal of Pharmacology and Experimental Therapeutics 1970; 175: 352-360.

Smith TW , Butler VP Jr, Haber E. Characterization of antibodies of high affinity and specificity for the digitalis glycoside digoxin. Biochemistry 1970; 9: 331-337.

10.

Schmidt DH , Butler VP Jr. Immunological protection against digoxin toxicity. Journal of Clinical Investigation 1971; 50: 866-871.

11.

Schmidt DH , Butler VP Jr. Reversal of digoxin toxicity with specific antibodies. Journal of Clinical Investigation 1971; 50: 1738-1744.

12.

Curd J. , Smith TW , Jaton JC , Haber E. The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin. Proceedings of the National Academy of Sciences of the United States of America (Washington ) 1971; 68: 2401-2406.

13.

Butler VP Jr, Schmidt DH , Smith TW Effect of Fab fragments of sheep antidigoxin antibody (Dig Ab) on serum concentrations and urinary excretion of digoxin (dig). Circulation (New York) 1973; 48: 130.

14.

Smith TW , Haber E. , Yeatman L. , Butler VP Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. New England Journal of Medicine ( Boston) 1976; 294: 797-800.

15.

Ochs HR , Smith TW Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. Journal of Clinical Investigation 1977; 60: 1303-1313.

16.

Hess T. et al. Treatment of a case of lanatoside intoxication with digoxin specific Fab antibody fragments. American Heart Journal (St. Louis) 1979; 98: 767-771.

17.

Aeberhard P. et al. Le traitement d'une intoxication digitalique massive (20 mg de digitoxine) par les anticorps anti-digoxine fractionnés (Fab). Archives des Maladies du Coeur et des Vaisseaux (Paris) 1980; 73: 1471-1478.

18.

Scherrmann JM

Antibody treatment of toxin poisoning. Recent advances. Journal of Toxicology

Clinical Toxicology 1994; 32: 363-375.

19.

Dart RC et al. Ovine desipramine antibody fragments reverse desipramine cardiovascular toxicity in the rat. Annals of Emergency Medicine 1996; 27: 309-315.

20.

Schaumann W. , Kaufmann B. , Neubert P. , Smolarz A. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. European Journal of Clinical Pharmacology (Berlin) 1986; 30: 527-533.

21.

Porter RR The hydrolysis of rabbit gamma globulin and antibodies with crystalline papain . Biochemical Journal (London) 1959; 73: 119-126.

22.

Boyer L. et al. Coagulopathy in crotalid envenomation treated with a new Fab antivenom [Abstract]. Journal of Toxicology Clinical Toxicology 1996; 34: 593.

23.

Seifert SA et al. Correlation of venom effects, antivenom levels and venom antigenemia in a patient with Crotalus atrox envenomation treated with a Fab antivenom [Abstract]. Journal of Toxicology Clinical Toxicology 1996; 34: 593.

24.

Audebert F. et al. Pharmacokinetics of Vipera aspis venom after experimental envenomation in rabbits. Journal of Pharmacology and Experimental Therapeutics 1994; 268: 1512-1517.

25.

Pentel PR et al. Effects of drug-specific polyclonal Fab on desipramine cardiotoxicity and lethality in rats [Abstract]. Veterinary and Human Toxicology 1994; 36: 362.

26.

Egen N. et al. A new ovine antivenom for North American venomous snakes [Abstract] . Veterinary and Human Toxicology 1994; 36: 362.

27.

Taboulet P. , Baud FJ , Bismuth C. Clinical features and management of digitalis poisoning: Rationale for immunotherapy . Journal of Toxicology Clinical Toxicology 1993; 31: 247-260.

28.

Antman EM et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: Final report of a multicenter study. Circulation (New York) 1990; 81: 1744-1752.

29.

Hickey AR et al. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. Journal of the American College of Cardiology 1991 ; 17: 590-598.

30.

Smolarz A. et al. Digoxin specific antibody (Fab) fragments in 34 cases of severe digitalis intoxication. Journal of Toxicology Clinical Toxicology 1985; 23: 327-340.

31.

Warren HS , Danner RL , Munford RS Anti-endotoxin monoclonal antibodies. New England Journal of Medicine (Boston) 1992; 326: 1153-1157.

32.

Fink MP

Adoptive immunotherapy of gram-negative sepsis: Use of monoclonal antibodies to lipopolysaccharide. Critical

Care Medicine ( New York) 1993; 21: 32-39.

33.

Fisher CJ Jr et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. New England Journal of Medicine (Boston) 1996; 334: 1697-1702.

34.

Cohen J. , Heumann D. , Glauser MP Do monoclonal antibodies still have a future in infectious diseases ? American Journal of Medicine (New York ) 1995; 99: 45S-52S.

35.

Wolff J. , Capraro HG , Brossi A. , Cook GH Colchicine binding to antibodies. Journal of Biological Chemistry 1980; 255: 7144-7148.

36.

Terrien N. , Urtizberea M. , Scherrmann JM Immunotoxicotherapy for colchicine poisoning: Toxicological and pharmacological features of an experimental model simulating human poisoning. Archives of Toxicology and Industrial Hygiene 1988; 244: 322-325.

37.

Terrien N. , Urtizberea M. , Scherrmann JM Reversal of advanced colchicine toxicity in mice with goat colchicine-specific antibodies. Toxicology and Applied Pharmacology ( New York) 1990; 104: 504-510.

38.

Terrien N. , Urtizberea M. , Scherrmann JM Influence of goat colchicine-specific antibodies on murine colchicine disposition . Toxicology (Amsterdam) 1989; 59: 11-22.

39.

Scherrmann JM , Urtizberea M. , Pierson P. , Terrien N. The effect of colchicine-specific active immunization on colchicine toxicity and disposition in the rabbit. Toxicology (Amsterdam ) 1989; 56: 213-222.

40.

Rouan SE et al. Reversal of colchicine-induced mitotic arrest in Chinese hamster cells with a colchicine-specific monoclonal antibody. American Journal of Pathology (Philadelphia) 1990; 137: 779-787.

41.

Baud FJ et al. Treatment of severe colchicine overdose with colchicine-specific Fab fragments. New England Journal of Medicine ( Boston) 1995; 332: 642-645.

42.

Pepin-Covatta S. , Lutsch C. , Grandgeorge M. , Scherrmann J-M. Immunoreactivity of a new generation of horse F(ab')2 preparations against European viper venoms and the tetanus toxin . Toxicon 1996; In Press.

43.

Pepin-Covatta S. et al. Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions. Toxicology and Applied Pharmacology (New York ) 1996; In Press.

44.

Sjostrom L. et al. Development and clinical application of immunoassays for European adder (Vipera berus berus) venom and antivenom . Toxicon 1996; 34: 91-98.

45.

Gateau T. , Bloom M. , Clark R. Response to specific Centruroides sculpturatus antivenom in 151 cases of scorpion stings. Journal of Toxicology Clinical Toxicology 1994; 32: 165-171.

46.

Litovitz T. , Clark LR , Soloway RA 1993 Annual report of the American Association of Poison Control Centers toxic exposure surveillance system. American Journal of Emergency Medicine 1994; 12: 546-586.

47.

Pentel PR et al. Reduction of desipramine cardiotoxicity and prolongation of survival in rats with the use of polyclonal drug-specific antibody Fab fragments . Annals of Emergency Medicine 1995; 26: 334-341.

48.

Pentel PR et al. Reversal of desipramine toxicity in rats with polyclonal drug-specific antibody Fab fragments. Journal of Laboratory and Clinical Medicine 1993; 123: 387-393.

49.

Brunn GJ , Keyler DE , Pond SM , Pentel PR Reversal of desipramine toxicity in rats using drug-specific antibody Fab' Fragment: Effects on hypotension and interaction with sodium bicarbonate . Journal of Pharmacology and Experimental Therapeutics 1992 ; 260: 1392-1399.

50.

Pentel PR , Keyler DE Drug-specific antibodies as antidotes for tricyclic antidepressant overdose . Toxicology Letters 1995; 82/83: 801-806.

51.

Huston Js et al. Medical applications of single-chain antibodies . Internation Review of Immunology 1993; 10: 195-217.

52.

Berkowitz B. , Spector S. Evidence for active immunity to morphine in mice. Science 1972; 178: 1290-1292.

53.

Carrera RA et al. Suppression of psychoactive effects of cocaine by active immunization . Nature 1995; 378: 727-730.

Immunotoxicotherapy: Successes,disappointments and hopes

Abstract

Keywords

Get full access to this article

References